CXCL9/10-engineered dendritic cells promote T cell activation and enhance immune checkpoint blockade for lung cancerRaymond J. Lim, Bin Liu, Ramin Salehi‐Rad et al.|Cell Reports Medicine|2024Cited by 111
CCL21-DC in situ vaccination in murine NSCLC overcomes resistance to immunotherapy and generates systemic tumor-specific immunityRamin Salehi‐Rad, Steven M. Dubinett, Stacy J. Park et al.|Journal for ImmunoTherapy of Cancer|2023Cited by 30
Single-Cell Characterization of Pulmonary Nodules Implicates Suppression of Immunosurveillance across Early Stages of Lung AdenocarcinomaJane Yanagawa, Steven M. Dubinett, Linh M. Tran et al.|Cancer Research|2023Cited by 19
Characteristics of a <i>CCL21</i> Gene–Modified Dendritic Cell Vaccine Utilized for a Clinical Trial in Non–Small Cell Lung CancerMichael S. Oh, Bin Liu, Camelia Dumitras et al.|Molecular Cancer Therapeutics|2024Cited by 10
Genotoxic Treatment Enhances Immune Response in a Genetic Model of Lung CancerPasquale Saggese, Claudio Scafoglio, C. Jiménez Martínez et al.|Cancers|2021Cited by 7